HEK

ExcellGene SA and Cytovance Biologics Join Forces to Transform Large Molecule Biologics Development and Manufacture

Retrieved on: 
Wednesday, May 8, 2024
Other Manufacturing, Research, Genetics, Manufacturing, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Immortalised cell line, Chinese hamster, Partnership, Doctor of Philosophy, CHO, HEK, CDMO, Therapy, Multimedia, Organization, Fine chemical

ExcellGene SA, a leading Swiss biotech service provider specializing in mammalian cell line development for more than two decades, proudly announces its strategic collaboration with Cytovance Biologics , a renowned Contract Development and Manufacturing Organization (CDMO) based in the USA.

Key Points: 
  • ExcellGene SA, a leading Swiss biotech service provider specializing in mammalian cell line development for more than two decades, proudly announces its strategic collaboration with Cytovance Biologics , a renowned Contract Development and Manufacturing Organization (CDMO) based in the USA.
  • View the full release here: https://www.businesswire.com/news/home/20240508752875/en/
    Cytovance Biologics, an established US-based CDMO, is joining forces with ExcellGene SA, a leader in mammalian cell line development.
  • Their collaboration brings ExcellGene's advanced transposon technologies to customers looking to optimize CHO and HEK cell lines for biopharma production.
  • "We are thrilled to partner with Cytovance Biologics, a company that shares our commitment to excellence and innovation in biopharmaceutical manufacturing,” said Maria Wurm, CEO of ExcellGene SA.

NewBiologix Licenses Florabio’s HEK293 Cell Line for the Generation of Novel and Proprietary Cell Lines for the Stable Expression of rAAVs used in Gene Therapy

Retrieved on: 
Tuesday, February 27, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Health Technology, HEK, HEK293, Immortalised cell line, AAV, Research, Cell, Patient, Fine chemical

NewBiologix’s innovative approach stands to replace the industry-standard transient transfection methods, offering a stable, more reliable, and scalable solution for biopharmaceutical companies developing gene therapies.

Key Points: 
  • NewBiologix’s innovative approach stands to replace the industry-standard transient transfection methods, offering a stable, more reliable, and scalable solution for biopharmaceutical companies developing gene therapies.
  • Under the terms of the agreement, NewBiologix acquired rights to use Florabio’s HEK293 suspension cell line for research and commercial applications.
  • Leveraging proprietary genomic data, NewBiologix plans to engineer the Florabio HEK293 cell line and select highly characterized clones with exceptional growth, expansion, and transfectability properties.
  • NewBiologix will achieve its goals faster and more efficiently by starting with the 'FlorabioHEK293' cell line and our chemically defined HEK293 medium.”

OncoNano Medicine Announces Positive Preclinical Data for ON-BOARD™ IL-12 Program at SITC 2023 Annual Meeting

Retrieved on: 
Friday, November 3, 2023
Science, Biotechnology, Research, Surgery, Oncology, Health, Health Technology, Clinical Trials, Survival, IND, Therapy, Cytokine, Doctor of Philosophy, CD8, HEK, Neoplasm, NK, Research and development, Animal, Cancer, Pharmaceutical industry, Extractive metallurgy

The study also found that ON-BOARD™ significantly improved the tolerability of IL-12Fc, as compared to unencapsulated IL-12.

Key Points: 
  • The study also found that ON-BOARD™ significantly improved the tolerability of IL-12Fc, as compared to unencapsulated IL-12.
  • The encapsulated IL-12Fc demonstrated potent anti-tumor efficacy and durable anti-tumor memory in the MC38 colorectal cancer model.
  • ONM-412, the development product candidate with the IL-12 encapsulated in the ON-BOARD™ polymeric micelle system, is advancing through IND-enabling activities.
  • - ON-BOARD™ encapsulated IL-12Fc exhibited potent anti-tumor efficacy and prolonged survival in MC38 tumor-bearing animals with long-term memory effect.

Ganymede Bio and Kytopen Partner to Bring Cloud-Native, Structured Data to Gene-Modified Cell Therapy Instruments

Retrieved on: 
Tuesday, September 19, 2023
Partnership, Health, PALO, Interoperability, Cell, Patent, Patient, Paper, HEK, FAIR, Video game, Medical imaging, Findability, Ganymede

The company's software automatically integrates every piece of data from every source into a single cloud location.

Key Points: 
  • The company's software automatically integrates every piece of data from every source into a single cloud location.
  • Kytopen's customers will be able to:
    "In biotech, data is the bedrock of every patent, paper, and product.
  • Kytopen's groundbreaking Flowfect® platform has demonstrated compelling performance in primary cell transfection, including with CAR-T and HEK cell lines.
  • In the near future, Kytopen customers will be able to seamlessly integrate data from their Flowfect® instruments with any application and existing data infrastructure via Ganymede's platform.

POINT Biopharma Expands Its Research with Next-Generation Isotopes, Publishing New Preclinical Data at SNMMI’s Annual Congress

Retrieved on: 
Monday, June 26, 2023
Terbium, Society, SNMMI, Radionuclide, Survival, FAP, Poster, Isotope, HEK, Actinium-225, Rare-earth element, Medical imaging

INDIANAPOLIS, June 26, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced the publication of preclinical data from their pan-cancer, fibroblast activation protein-α (FAP)-targeted program, PNT2004, at the 2023 Annual Meeting of the Society of Nuclear Medicine & Molecular Imaging (SNMMI), taking place June 24-27, 2023, in Chicago, IL.

Key Points: 
  • PNT6555, the lead candidate in the PNT2004 program, led to complete and durable tumor regression and improved survival in HEK-mFAP tumor-bearing mice when chelated to any one of the three radioisotopes studied: lutetium-177 (177Lu), actinium-225 (225Ac), and terbium-161 (161Tb).
  • Additionally, 177Lu-PNT6555 in combination with anti-PD-1 checkpoint blockade was assessed in the aggressive, immunocompetent CT26-mFAP mouse model and demonstrated a significant survival benefit compared to either treatment alone.
  • “By continuing to develop expertise in more isotopes, POINT is better positioned to create optimized next-generation radioligands, which match a ligand’s properties with the most appropriate isotope,” said Joe McCann, Ph.D., Chief Executive Officer of POINT Biopharma.
  • “The expertise to discover and develop new radioligands and advance them into clinical trials has been built into POINT.

Cell Line Development Services Global Market Report 2022-2030: Increasing Trend of Biologics Outsourcing and Increasing Approval and Demand for Biologics and Biosimilars - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 10, 2023
Health, Biotechnology, Raptr, Immortalised cell line, CHO, Geography, Sirna, Infection, N-Glycolylneuraminic acid, Growth, CLD, HEK, Therapy, BHK, Nanofluid, Degenerative disease, Research, CDMO, Incidence, CDO, GMP, Cell, Renewable energy, Vaccine, Fine chemical, Mobile phone, Hybridoma technology

The "Cell Line Development Services Global Market - Forecast To 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cell Line Development Services Global Market - Forecast To 2030" report has been added to ResearchAndMarkets.com's offering.
  • Increasing trend of biologics outsourcing and increasing approval and demand for biologics and biosimilars are driving the market.
  • Cell line development service global market is classified based on the expression system, cell line type, application and geography.
  • Based on expression system, cell line development service global market is segmented into microbial, mammalian and others.

Global Protein Expression Market Report 2022 to 2027: Emergence of Microfluidics Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 2, 2022
Biotechnology, Health, Science, Other Science, Research, Awareness, Growth, Region, Protein expression, CHO, HEK, Reagent, Prokaryote, Pichia, CAGR, Investment, USD, Competency management system, Prevalence, Therapy, Fine chemical

The global Protein Expression market is valued at an estimated USD 2.9 billion in 2022 and is projected to reach USD 5.4 billion by 2027, at a CAGR of 13.3% during the forecast period.

Key Points: 
  • The global Protein Expression market is valued at an estimated USD 2.9 billion in 2022 and is projected to reach USD 5.4 billion by 2027, at a CAGR of 13.3% during the forecast period.
  • Factors such as the growth in the life science and biopharmaceutical industries, increasing research activities on recombinant-based protein expression, and the availability of funding for protein-based research.
  • However, the high cost of protein expression reagents and instruments is expected to restrain the growth of this market.
  • The Prokaryotic Expression system segment accounted for the highest growth rate in the Protein Expression market, by System Type, during the forecast period
    In 2021, the Prokaryotic Expression system segment accounted for the highest growth rate.

Ray Therapeutics and Forge Biologics Expand Their Viral Vector cGMP Partnership to Encompass Plasmid DNA Manufacturing

Retrieved on: 
Monday, October 10, 2022
Other Manufacturing, Research, Genetics, Clinical Trials, Manufacturing, Biotechnology, Health, Pharmaceutical, Science, Ignition, CA, Retina, Therapy, Retinal ganglion cell, Prevalence, Optogenetics, Retinal degeneration, Field line, Light, CGMP, Person, Biotechnology, Patient, B cell, Research, Program, Multimedia, Â, Severe cognitive impairment, Plasmid, Partnership, Retinitis, Visual acuity, Nyctalopia, Neuron, Ray, AAV, RP, CEO, RGC, DNA, Central retinal artery occlusion, HEK, Retinitis pigmentosa, Pharmaceutical industry, Vaccine, Hearth, Forge

View the full release here: https://www.businesswire.com/news/home/20221010005240/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221010005240/en/
    Forge will provide research-grade and GMP-Pathway plasmid manufacturing services, in addition to adeno-associated viral vector (AAV) process development, scale-up engineering, and cGMP manufacturing services for Ray Therapeutics program, RTx-015.
  • The program will continue to utilize Forges platform manufacturing processes, including its proprietary HEK 293 suspension Ignition Cells and pEMBR adenovirus helper plasmid.
  • All development and cGMP manufacturing activities will occur at the Hearth, Forges 200,000 square foot gene therapy cGMP production facility in Columbus, Ohio.
  • Ray Therapeutics lead candidate RTx-015 uses intravitreal administration, from which the vector diffuses into the retina and transduces primarily the RGCs.

Advanced Instruments Acquires SAL Scientific, Expertise, and a Range of Cell Growth Supplements in Support of Research & Drug Discovery Workflows

Retrieved on: 
Monday, August 1, 2022
Acquisition, CHO, CEO, Hamster, Solution, Immortalised cell line, Investor AB, HEK, Adoption, Technology, Biology, CLD, Growth, Workflow, Fine chemical

These reagents substantially improve cell growth under stressful conditions and help accelerate cell line development (CLD) biology workflows to maximize biotherapeutic production.

Key Points: 
  • These reagents substantially improve cell growth under stressful conditions and help accelerate cell line development (CLD) biology workflows to maximize biotherapeutic production.
  • The acquisition expands Advanced Instruments' reagent expertise and furthers its commitment to bioprocess workflows for advanced therapies.
  • SAL Scientific is the developer and manufacturer of the InstiGRO, InstiSHAKE, and InstiTHAW Cell Growth Supplements that Advanced Instruments exclusively distributes today.
  • "As an existing commercial partner, we recognize the strong synergy between the Insti supplements and the Advanced Instruments cell line development systems.

Advanced Instruments Acquires SAL Scientific, Expertise, and a Range of Cell Growth Supplements in Support of Research & Drug Discovery Workflows

Retrieved on: 
Monday, August 1, 2022
Acquisition, CHO, CEO, Hamster, Solution, Immortalised cell line, Investor AB, HEK, Adoption, Technology, Biology, CLD, Growth, Workflow, Fine chemical

These reagents substantially improve cell growth under stressful conditions and help accelerate cell line development (CLD) biology workflows to maximize biotherapeutic production.

Key Points: 
  • These reagents substantially improve cell growth under stressful conditions and help accelerate cell line development (CLD) biology workflows to maximize biotherapeutic production.
  • The acquisition expands Advanced Instruments' reagent expertise and furthers its commitment to bioprocess workflows for advanced therapies.
  • SAL Scientific is the developer and manufacturer of the InstiGRO, InstiSHAKE, and InstiTHAW Cell Growth Supplements that Advanced Instruments exclusively distributes today.
  • "As an existing commercial partner, we recognize the strong synergy between the Insti supplements and the Advanced Instruments cell line development systems.